Rafferty Asset Management LLC Trims Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Rafferty Asset Management LLC decreased its stake in Regeneron Pharmaceuticals by 6.1%, holding 44,702 shares worth approximately $28.35 million.
• Regeneron's latest earnings report showed an EPS of $12.89, significantly beating analyst expectations of $8.43, with quarterly revenue increasing by 3.6% year-over-year.
• The company recently declared a quarterly dividend of $0.88 per share, resulting in an annualized yield of 0.6%.

Rafferty Asset Management LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,702 shares of the biopharmaceutical company's stock after selling 2,906 shares during the quarter. Rafferty Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $28,351,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. American Assets Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $427,000. Integrated Wealth Concepts LLC boosted its stake in shares of Regeneron Pharmaceuticals by 55.5% during the 4th quarter. Integrated Wealth Concepts LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $828,000 after acquiring an additional 415 shares during the last quarter. Kovitz Investment Group Partners LLC grew its position in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,839 shares of the biopharmaceutical company's stock valued at $2,735,000 after acquiring an additional 148 shares during the period. Finally, Capital Analysts LLC increased its stake in shares of Regeneron Pharmaceuticals by 21.0% in the 4th quarter. Capital Analysts LLC now owns 397 shares of the biopharmaceutical company's stock worth $283,000 after purchasing an additional 69 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $7.35 during midday trading on Thursday, hitting $579.61. 616,549 shares of the company traded hands, compared to its average volume of 1,082,231. The stock has a market cap of $61.43 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 1.96 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,210.97. The firm has a 50 day moving average of $555.84 and a 200-day moving average of $588.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm earned $11.56 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.